UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 315,813 Shares of CME Group Inc. (NASDAQ:CME)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in CME Group Inc. (NASDAQ:CME - Free Report) by 14.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,437,662 shares of the financial services provider's stock after acquiring an additional 315,813 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.68% of CME Group worth $566,098,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Waverly Advisors LLC lifted its holdings in shares of CME Group by 32.2% in the 4th quarter. Waverly Advisors LLC now owns 10,827 shares of the financial services provider's stock worth $2,514,000 after acquiring an additional 2,637 shares during the last quarter. Woodline Partners LP bought a new stake in shares of CME Group in the 4th quarter worth approximately $5,026,000. Sone Capital Management LLC bought a new stake in shares of CME Group in the 4th quarter worth approximately $8,049,000. Vident Advisory LLC lifted its holdings in shares of CME Group by 125.7% in the 4th quarter. Vident Advisory LLC now owns 17,072 shares of the financial services provider's stock worth $3,965,000 after acquiring an additional 9,508 shares during the last quarter. Finally, Southpoint Capital Advisors LP purchased a new position in shares of CME Group in the fourth quarter worth $116,115,000. 87.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CME. Piper Sandler lifted their target price on shares of CME Group from $275.00 to $283.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 8th. Barclays lifted their target price on shares of CME Group from $279.00 to $283.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 23rd. Morgan Stanley lifted their target price on shares of CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Keefe, Bruyette & Woods lifted their target price on shares of CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research note on Thursday, April 24th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $269.00 target price on shares of CME Group in a research note on Thursday, April 3rd. Three analysts have rated the stock with a sell rating, seven have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, CME Group has an average rating of "Hold" and an average price target of $256.80.

Insider Transactions at CME Group

In related news, Director Howard J. Siegel sold 10,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $260.00, for a total value of $2,600,000.00. Following the transaction, the director now owns 21,873 shares in the company, valued at $5,686,980. The trade was a 31.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Phyllis M. Lockett sold 1,060 shares of the company's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $277.88, for a total transaction of $294,552.80. Following the completion of the transaction, the director now owns 3,108 shares in the company, valued at approximately $863,651.04. The trade was a 25.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,494 shares of company stock valued at $7,281,618 in the last three months. 0.30% of the stock is currently owned by company insiders.

CME Group Stock Down 0.0%

Shares of CME Group stock opened at $277.87 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10. The company's fifty day simple moving average is $266.65 and its two-hundred day simple moving average is $247.92. The company has a market cap of $100.13 billion, a P/E ratio of 28.74, a PEG ratio of 6.76 and a beta of 0.45. CME Group Inc. has a 12-month low of $190.70 and a 12-month high of $286.48.

CME Group (NASDAQ:CME - Get Free Report) last released its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. The firm had revenue of $1.64 billion for the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a net margin of 57.52% and a return on equity of 13.62%. The company's revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.50 EPS. Research analysts anticipate that CME Group Inc. will post 10.49 EPS for the current year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th will be given a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date of this dividend is Monday, June 9th. CME Group's dividend payout ratio is presently 50.30%.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.